Association between SARS-CoV-2 infection and select symptoms and conditions 31 to 150 days after testing among children and adults
© 2024. The Author(s)..
BACKGROUND: An increasing number of studies have described new and persistent symptoms and conditions as potential post-acute sequelae of SARS-CoV-2 infection (PASC). However, it remains unclear whether certain symptoms or conditions occur more frequently among persons with SARS-CoV-2 infection compared with those never infected with SARS-CoV-2. We compared the occurrence of specific COVID-associated symptoms and conditions as potential PASC 31- to 150-day following a SARS-CoV-2 test among adults and children with positive and negative test results.
METHODS: We conducted a retrospective cohort study using electronic health record (EHR) data from 43 PCORnet sites participating in a national COVID-19 surveillance program. This study included 3,091,580 adults (316,249 SARS-CoV-2 positive; 2,775,331 negative) and 675,643 children (62,131 positive; 613,512 negative) who had a SARS-CoV-2 laboratory test during March 1, 2020-May 31, 2021 documented in their EHR. We used logistic regression to calculate the odds of having a symptom and Cox models to calculate the risk of having a newly diagnosed condition associated with a SARS-CoV-2 positive test.
RESULTS: After adjustment for baseline covariates, hospitalized adults and children with a positive test had increased odds of being diagnosed with ≥ 1 symptom (adults: adjusted odds ratio[aOR], 1.17[95% CI, 1.11-1.23]; children: aOR, 1.18[95% CI, 1.08-1.28]) or shortness of breath (adults: aOR, 1.50[95% CI, 1.38-1.63]; children: aOR, 1.40[95% CI, 1.15-1.70]) 31-150 days following a SARS-CoV-2 test compared with hospitalized individuals with a negative test. Hospitalized adults with a positive test also had increased odds of being diagnosed with ≥ 3 symptoms or fatigue compared with those testing negative. The risks of being newly diagnosed with type 1 or type 2 diabetes (adjusted hazard ratio[aHR], 1.25[95% CI, 1.17-1.33]), hematologic disorders (aHR, 1.19[95% CI, 1.11-1.28]), or respiratory disease (aHR, 1.44[95% CI, 1.30-1.60]) were higher among hospitalized adults with a positive test compared with those with a negative test. Non-hospitalized adults with a positive test also had higher odds or increased risk of being diagnosed with certain symptoms or conditions.
CONCLUSIONS: Patients with SARS-CoV-2 infection, especially those who were hospitalized, were at higher risk of being diagnosed with certain symptoms and conditions after acute infection.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
BMC infectious diseases - 24(2024), 1 vom: 10. Feb., Seite 181 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Yongkang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 pandemic |
|---|
| Anmerkungen: |
Date Completed 14.02.2024 Date Revised 19.02.2024 published: Electronic UpdateOf: medRxiv. 2022 Dec 19;:. - PMID 36597540 Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12879-024-09076-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368310825 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368310825 | ||
| 003 | DE-627 | ||
| 005 | 20240219232050.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240211s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12879-024-09076-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1299.xml |
| 035 | |a (DE-627)NLM368310825 | ||
| 035 | |a (NLM)38341566 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhang, Yongkang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Association between SARS-CoV-2 infection and select symptoms and conditions 31 to 150 days after testing among children and adults |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2024 | ||
| 500 | |a Date Revised 19.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateOf: medRxiv. 2022 Dec 19;:. - PMID 36597540 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a BACKGROUND: An increasing number of studies have described new and persistent symptoms and conditions as potential post-acute sequelae of SARS-CoV-2 infection (PASC). However, it remains unclear whether certain symptoms or conditions occur more frequently among persons with SARS-CoV-2 infection compared with those never infected with SARS-CoV-2. We compared the occurrence of specific COVID-associated symptoms and conditions as potential PASC 31- to 150-day following a SARS-CoV-2 test among adults and children with positive and negative test results | ||
| 520 | |a METHODS: We conducted a retrospective cohort study using electronic health record (EHR) data from 43 PCORnet sites participating in a national COVID-19 surveillance program. This study included 3,091,580 adults (316,249 SARS-CoV-2 positive; 2,775,331 negative) and 675,643 children (62,131 positive; 613,512 negative) who had a SARS-CoV-2 laboratory test during March 1, 2020-May 31, 2021 documented in their EHR. We used logistic regression to calculate the odds of having a symptom and Cox models to calculate the risk of having a newly diagnosed condition associated with a SARS-CoV-2 positive test | ||
| 520 | |a RESULTS: After adjustment for baseline covariates, hospitalized adults and children with a positive test had increased odds of being diagnosed with ≥ 1 symptom (adults: adjusted odds ratio[aOR], 1.17[95% CI, 1.11-1.23]; children: aOR, 1.18[95% CI, 1.08-1.28]) or shortness of breath (adults: aOR, 1.50[95% CI, 1.38-1.63]; children: aOR, 1.40[95% CI, 1.15-1.70]) 31-150 days following a SARS-CoV-2 test compared with hospitalized individuals with a negative test. Hospitalized adults with a positive test also had increased odds of being diagnosed with ≥ 3 symptoms or fatigue compared with those testing negative. The risks of being newly diagnosed with type 1 or type 2 diabetes (adjusted hazard ratio[aHR], 1.25[95% CI, 1.17-1.33]), hematologic disorders (aHR, 1.19[95% CI, 1.11-1.28]), or respiratory disease (aHR, 1.44[95% CI, 1.30-1.60]) were higher among hospitalized adults with a positive test compared with those with a negative test. Non-hospitalized adults with a positive test also had higher odds or increased risk of being diagnosed with certain symptoms or conditions | ||
| 520 | |a CONCLUSIONS: Patients with SARS-CoV-2 infection, especially those who were hospitalized, were at higher risk of being diagnosed with certain symptoms and conditions after acute infection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 pandemic | |
| 650 | 4 | |a Electronic health record | |
| 650 | 4 | |a Long-COVID | |
| 650 | 4 | |a SARS-CoV-2 | |
| 700 | 1 | |a Romieu-Hernandez, Alfonso |e verfasserin |4 aut | |
| 700 | 1 | |a Boehmer, Tegan K |e verfasserin |4 aut | |
| 700 | 1 | |a Azziz-Baumgartner, Eduardo |e verfasserin |4 aut | |
| 700 | 1 | |a Carton, Thomas W |e verfasserin |4 aut | |
| 700 | 1 | |a Gundlapalli, Adi V |e verfasserin |4 aut | |
| 700 | 1 | |a Fearrington, Julia |e verfasserin |4 aut | |
| 700 | 1 | |a Nagavedu, Kshema |e verfasserin |4 aut | |
| 700 | 1 | |a Dea, Katherine |e verfasserin |4 aut | |
| 700 | 1 | |a Moyneur, Erick |e verfasserin |4 aut | |
| 700 | 1 | |a Cowell, Lindsay G |e verfasserin |4 aut | |
| 700 | 1 | |a Kaushal, Rainu |e verfasserin |4 aut | |
| 700 | 1 | |a Mayer, Kenneth H |e verfasserin |4 aut | |
| 700 | 1 | |a Puro, Jon |e verfasserin |4 aut | |
| 700 | 1 | |a Rasmussen, Sonja A |e verfasserin |4 aut | |
| 700 | 1 | |a Thacker, Deepika |e verfasserin |4 aut | |
| 700 | 1 | |a Weiner, Mark G |e verfasserin |4 aut | |
| 700 | 1 | |a Saydah, Sharon |e verfasserin |4 aut | |
| 700 | 1 | |a Block, Jason P |e verfasserin |4 aut | |
| 700 | 0 | |a PCORnet Network Partners |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmad, Faraz S |e investigator |4 oth | |
| 700 | 1 | |a Bunnell, H Timothy |e investigator |4 oth | |
| 700 | 1 | |a Carrasquillo, Olveen |e investigator |4 oth | |
| 700 | 1 | |a Chrischilles, Elizabeth A |e investigator |4 oth | |
| 700 | 1 | |a Christakis, Dimitri A |e investigator |4 oth | |
| 700 | 1 | |a Chang, Bernard P |e investigator |4 oth | |
| 700 | 1 | |a Curtis, Janis L |e investigator |4 oth | |
| 700 | 1 | |a Fernandez, Soledad A |e investigator |4 oth | |
| 700 | 1 | |a Forrest, Christopher B |e investigator |4 oth | |
| 700 | 1 | |a Fort, Daniel |e investigator |4 oth | |
| 700 | 1 | |a Hanauer, David A |e investigator |4 oth | |
| 700 | 1 | |a Hess, Rachel |e investigator |4 oth | |
| 700 | 1 | |a Horne, Benjamin D |e investigator |4 oth | |
| 700 | 1 | |a Giordano, Philip |e investigator |4 oth | |
| 700 | 1 | |a Hogan, William |e investigator |4 oth | |
| 700 | 1 | |a Mosa, Abu Saleh Mohammad |e investigator |4 oth | |
| 700 | 1 | |a McClay, James C |e investigator |4 oth | |
| 700 | 1 | |a Nandhakumar, Samyuktha |e investigator |4 oth | |
| 700 | 1 | |a Nolan, Bridget |e investigator |4 oth | |
| 700 | 1 | |a Obeid, Jihad S |e investigator |4 oth | |
| 700 | 1 | |a Ostasiewski, Brian |e investigator |4 oth | |
| 700 | 1 | |a Paranjape, Anuradha |e investigator |4 oth | |
| 700 | 1 | |a Patel, Lav |e investigator |4 oth | |
| 700 | 1 | |a Rao, Suchitra |e investigator |4 oth | |
| 700 | 1 | |a Robinson, Patricia S |e investigator |4 oth | |
| 700 | 1 | |a Trick, William E |e investigator |4 oth | |
| 700 | 1 | |a Silverstein, Jonathan C |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t BMC infectious diseases |d 2001 |g 24(2024), 1 vom: 10. Feb., Seite 181 |w (DE-627)NLM11120089X |x 1471-2334 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2024 |g number:1 |g day:10 |g month:02 |g pages:181 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12879-024-09076-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2024 |e 1 |b 10 |c 02 |h 181 | ||